RxDoctor Payments Data

Gary Jaffe, MD

Ophthalmology · Aventura, FLNPI 1962455824

Payments from drug & device makers

$1,746in general payments, 2019–2025

Across 59 payments — averaging $29.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$617
  • Amgen$510
  • Regeneron Healthcare Solutions, Inc.$120
  • Sight Sciences, Inc.$85
  • Alcon$83
  • Aerie Pharmaceuticals, Inc.$77
  • plus $254 from 10 others

What the payments were for

  • Food & beverage$1,70197%
  • Gifts$453%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,746 in reported general payments places this provider in the 45th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$108,845
Medicare patients
460
Services billed
949

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost146$72,644
RhopressaNetarsudil Mesylate139$54,774
RestasisCyclosporine48$42,567
CombiganBrimonidine Tartrate/Timolol113$37,808
RocklatanNetarsudil Mesylat/Latanoprost74$30,636
Latanoprost2,309$28,283
Timolol Maleate912$11,577
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol67$11,132
Alphagan PBrimonidine Tartrate33$10,634
Travoprost67$10,245
Brimonidine Tartrate447$8,549
SimbrinzaBrinzolamide/Brimonidine Tart27$6,144
Prednisolone Acetate130$4,153
Dorzolamide Hcl196$3,764
Timolol MaleateTimolol Maleate/Pf17$3,389

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$617$163,653340 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$77$85,410213 claims
AlconSimbrinza$83$6,14427 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Aventura

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →